Introduction
Leukemias are more susceptible to chemotherapy than are solid cancers, in part because leukemia cells readily undergo apoptosis, [1] [2] [3] [4] a form of cell death characterized by caspase activation. 5 The relationship between cell death and proteolysis is complex. 6 On the one hand, the quintessence of apoptotic cell death is the cleavage of proteins, and in some settings the involvement of calpain, lysosomal and proteasomal proteases have been documented. [7] [8] [9] [10] [11] [12] [13] [14] On the other hand, numerous inhibitors of proteolysis induce apoptosis. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Apoptosis can be induced by a variety of stimuli, including the p53 tumor suppressor. 25 Besides wt p53, other tumor suppressors such as p27 26 and BRCA1 27 can induce apoptosis. Most of these proteins are degraded by the proteasome, 28, 29 whereas BRCA1 is mostly degraded by cathepsin. 30 Therefore, inhibitors of proteolysis up-regulate potentially pro-apoptotic proteins.
Traditionally, apoptosis has been considered to be p53-dependent if it is associated with wt p53 induction. Wt p53 is degraded by the proteasome [31] [32] [33] and at least in vitro potentially by calpain. [34] [35] [36] This association between p53 accumulation and apoptosis has led to the suggestion that apoptosis following inhibition of proteolysis may be p53-dependent. 15, 16 Correspondence: MV Blagosklonny; Fax: (301) 402-0172 Received 3 November 1999; accepted 8 March 2000 The ability to induce wt p53 and apoptosis varies among nonselective protease inhibitors, in part due to different and overlapping activities toward the proteasome, calpain and cathepsin.
Here, we demonstrate that inhibition of the proteasome is primarily responsible for wt p53 accumulation following treatment with inhibitors of cellular proteases. Furthermore, proteasome inhibition, but not inhibition of other proteases, induces apoptosis in apoptosis-sensitive cells. However, wt p53 is neither sufficient nor essential for apoptosis caused by proteasome inhibitors. Thus, induction of wt p53 and apoptosis represent two independent markers of proteasome inhibition.
Materials and methods

Cell lines and reagents
The human cancer cell lines used in this study include the breast-derived lines MCF7, the prostate-derived PC3 and PC3M, LNCaP; the leukemia-derived Jurkat, MOLT-4, K562, HL60, and U937. The human colon cancer cell line HCT116, and a clone lacking p21 (p21−/−), generated from HCT116 cells 37 were a gift from Drs B Vogelstein and T Waldman (Johns Hopkins University, Baltimore, MD, USA) and were cultivated as described previously. 32, 38 Lactacystin (LC), a specific proteasome inhibitor, was obtained from Calbiochem (La Jolla, CA, USA), prepared as a 2 mM stock solution in distilled water, and was used at 10 M final concentration. N-acetyl-leu-leu-norleucinal (ALLN) and N-acetyl-leu-leu-normethional (ALLM) were purchased from Sigma Chemical St Louis, MO, USA), prepared in DMSO. Cell permeable calpastatin peptide and the non-peptide calpain inhibitor PD150606 were purchased from Calbiochem. The proteasome inhibitor PS341 was obtained as a kind gift from Dr Peter Elliott, Proscript (Cambridge, MA, USA). The caspase inhibitor Z-VAD-fluoromethylketone (Z-VAD-FMK) was obtained from Enzyme Systems Products (Livermore, CA, USA).
p53 expression vector
Ad-p53, a wt p53 expressing replication-deficient adenovirus, and Ad-LacZ, a ␤-galactosidase expressing replicationdeficient adenovirus were obtained from Dr B Vogelstein. The viral titer was determined as previously described. 38 
Immunoblot analysis
Proteins were harvested in TNESVF buffer (50 mM Tris HCl (pH 7.5), 2 mM EDTA, 100 mM NaCl, 1 mM sodium orthovanadate, sodium fluoride, 1% NP-40) with protease inhibitors and were resolved on 12.5% SDS-PAGE, for p21 WAF1/CIP1 , and on 7.5% SDS-PAGE, for Rb, mdm-2, p53, and PARP detection as previously described. 39, 40 If indicated, proteins were resolved on a NuPAGE 4-12% Bis-Tris gel with MOPS running buffer (NOVEX, San Diego, CA, USA) according to the manufacturer's instructions. Immunoblot analysis was performed using the following antibodies: anti-human monoclonal WAF1 (EA10), p53 (Pab2), Rb, and mdm-2 antibodies (Oncogene Science, Calbiochem, San Diego, CA, USA), anti-PARP rabbit polyclonal (Upstate Biotechnology, Lake Placid, NY, USA).
MTT assay
2000-15000 cells were plated in 96-well flat bottom plates in 100 l of medium. 40 The next day, cells were exposed to the pharmacological agents. Two days after the last drug addition, 20 l of 5 mg/ml MTT solution in PBS was added to each well for 4 h. The medium was discarded, and 170 l DMSO was added to each well to dissolve the formazan crystals. The absorbance at 540 nm was determined using a Biokinetics plate reader (Bio-Tek Instruments, Winooski, VT, USA). Triplicate wells were assayed for each condition, the mean and standard deviations were determined.
Number of dead and live cells
Cells were plated in 24-well plates in 1 ml of medium. The next day, cells were treated with the drugs. After 3-4 days, cells were trypsinized and each condition was counted in triplicate on a Counter Z1 cell counter (Hialeah, FL, USA). In addition, cells were incubated with trypan blue and the numbers of blue (dead) cells and transparent (live) cells were counted in a hemocytometer.
Nuclear fragmentation assay
Jurkat cells were incubated with proteasome inhibitors with or without caspase inhibitors for 6 h. Cells were washed with PBS, pelleted on to glass slides in a cytocentrifuge, fixed with methanol and stained with DAPI as described previously. 41 Nuclei were visualized under UV microscopy.
Results
Cytotoxic effects of ALLM and ALLN
First we investigated the antiproliferative effects of ALLN, an inhibitor of the proteasome, calpain and cathepsin, which is also known as calpain inhibitor I. The sensitivity to ALLN varied markedly among the cell lines studied. Thus, the prostate cancer cell line PC3-M, and the breast cancer cell line MCF7 were resistant to ALLN, with an IC 50 Like ALLN, ALLM is also an inhibitor of calpain and cathepsin proteases, however, ALLN is 10-20 times less potent than ALLN as an inhibitor of the proteasome. Importantly, ALLM induced cytostatic and cytotoxic effects at doses 10-to 20-fold higher than ALLN (Figure 1b-e) . Since the ability to block calpain and cathepsin are similar for both inhibitors, 17 ,42 the concentration-dependent data indicate that inhibition of the proteasome is responsible for cytotoxicity. In agreement, PD 150606, a highly selective inhibitor of calpain 43 did not inhibit cell proliferation or survival (Figure 1f) .
Induction of wt p53 as a marker of proteasome inhibition
Wild-type (wt) p53 as well as the p53-inducible gene products p21 WAF1/CIP1 are degraded by the proteasome and, therefore, inhibitors of the proteasome induce accumulation of wt p53 and p21. 31, 32 We compared wt p53 accumulation and inhibition of cell growth after treatment with ALLN and ALLM. Prior to degradation by the proteasome, proteins become polyubiquitinated, and therefore, inhibition of the proteasome can be detected by accumulation of ubiquitinated proteins. Our data support previous observations that ALLN induces wt p53 at doses 20 times higher than ALLM. 34 ALLN and ALLM inhibit calpain I and II as well as cathepsin B with similar K i values between 5 and 12 nM. 42 Thus it would appear that the significant difference between these two inhibitors is that ALLN is 20 times more potent as a proteasome inhibitor than ALLM. Also, pure cathepsin inhibitors do not induce wt p53.
16,44
Inhibition of the proteasome and apoptosis in leukemia cells
As shown in Figure 1 , ALLN and ALMM at doses above 5 and 50 M were cytotoxic to Jurkat leukemia cells. At cytotoxic doses, these inhibitors induced the cleavage of PARP, Rb (Figure 3a) , and Raf-1 (data not shown), as an indicator of caspase activation/apoptosis. Thus, 20 M ALLM which did not induce cell death but inhibit proliferation (an IC 50 = 20 M) did not induce PARP cleavage. The PARP cleavage was detected at doses of ALLM which exceed 50 M (Figure 3) . Also, ALLN, at doses above 1 M, induced the cleavage of PARP and Rb proteins. Furthermore, PS-341, a highly selective inhibitor of proteasome, was more potent; and 1 M PS-341 caused disappearance of the 116 kDa band, whereas 1 M ALLN was ineffective.
The leukemia cell lines studied harbor mutant p53 (Jurkat 45, 46 ) or express no p53 protein (p53-null: HL60, K562, U937). Therefore, in these cells the proteasome inhibitorinduced apoptosis is independent of wt p53. The absence of wt p53, however, precludes use of wt p53 accumulation as a marker of proteasome inhibition in leukemia cell lines. We reasoned that accumulation of wt p53 as a marker of proteasome inhibition may be substituted for accumulation of any other proteasome-degraded protein. p21 WAF1/CIP1 (p21) protein is degraded by the proteasome. 32 As shown in Figure 3b , the accumulation of p21 correlated with cytotoxic effects of the inhibitors in cells lacking wt p53. 
Comparison of leukemia cell lines
Apoptosis is characterized by caspase activation which can be monitored by PARP cleavage. We compared the ability of proteasome inhibitors to induce PARP cleavage in a panel of leukemia cell lines. In contrast to Jurkat and HL60 cells, which are known easily to undergo apoptosis in response to numerous stimuli, 47, 48 K562 are resistant to many apoptotic stimuli. [49] [50] [51] [52] We found that K562 cells were relatively resistant to apoptosis caused by proteasome inhibitors (Figure 4) . The order of sensitivity of leukemia cells was: JurkatϾHL60ϾU937 K562. Thus, in Jurkat cells, both ALLN and PS-341 caused complete PARP cleavage by 10 h (Figure 4) . In HL60 cells, a half-maximal cleavage was observed by 10 h of ALLN treatment. In K562 cells, PARP cleavage was only detected by 20 h of exposure to the most active inhibitor, PS-341 (Figure 4) .
More selective proteasome inhibitors were more potent inducers of apoptosis and induced cell death faster (PS341 ALLN ALLM). It is possible that other activities of nonselective inhibitors counterbalance the pro-apoptotic activity of proteasome inhibition.
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Figure 4
Comparison of leukemia cell lines. Jurkat, HL60, U937, and K562 cells were incubated with 10 M ALLM, 10 M ALLN, or 1 M PS-341 for the indicated time. Then, cells were lysed and immunoblot analysis for PARP was performed as described in Methods.
Effect of caspase inhibitors on PS-341-induced apoptosis in Jurkat
In Jurkat cells, PARP cleavage, which coincides with nucleus fragmentation, develops by 2-6 h following exposure to PS-341 (Figure 5a and b) . Cell viability, as measured by MTT assay, drops by 12 h, and all cells were dead by 24-36 h at doses of PS-341 exceeding 10 nM, with an IC 50 of 5 nM by 36 h (Figure 5c ). Drop in the viability of Jurkat cells occurred at 12 h and this can be partially reversed by Z-VAD-FMK (Figure 5c ). This inhibitor prevented PARP cleavage, and nuclear fragmentation (Figure 5a and b) , and although delayed did not ultimately prevent cell death (Figure 5c ).
No effect of p53 overexpression or p21 deletion
Although proteasome inhibitors induce apoptosis in p53-negative cells, the intrinsic induction of wt p53 in wt p53-positive cells precludes ruling out the role of wt p53 in apoptosis. In the present study, we took advantage of the ability of a wt p53-expressing adenovirus (Ad-p53) to infect human cancer cells with 100% efficiency and to rapidly express wt p53 without selection for any additional traits. [53] [54] [55] This approach allows evaluation of the effect of wt p53 on sensitivity to proteasome inhibitors in p53 null cells. We found that rather than increasing apoptotic susceptibility, the expression of wt p53 marginally conferred resistance to PS-341 in PC3
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Figure 5
The effect of caspase inhibitors on PS341-induced apoptosis in Jurkat cells. (a) PARP cleavage. Cells were treated for 6 h with 100 nM PS-341 plus the caspase inhibitor Z-VAD-FMK (PS+Z-VAD), or left untreated (control). Immunoblot analysis for PARP was performed as described in Methods. (b) Nuclear fragmentation. Cells were treated for 6 h with 100 nM PS-341, PS-341 plus the caspase inhibitor Z-VAD-FMK (PS+Z-VAD), or left untreated (control). Nuclei were stained with DAPI as described in Methods. (c) Cytotoxicity at 12 and 36 h with Z-VAD-FMK or without Z-VAD-FMK. The MTT assay was performed as described in Methods. The mean ± s.d. of three experiments are shown as percent of untreated control. cells (Figure 6a) . Susceptibility of p53-null PC3 cells to apoptosis induced by proteasome inhibition has been previously reported, 21, 56 which leads to the suggestion that the apoptosis may be p53-independent. 56 Here, by reintroduction of wt p53, we proved that wt p53 does not contribute to the cell death caused by the proteasome inhibitor. Interestingly, PC3M, a clone of PC3 cells, was more resistant to cytotoxicity caused by PS-341 than the parental PC3 cells. Also, in PC3M cells, Ad-p53 did not increase sensitivity to PS-341. In contrast, Ad-p53 increased toxicity caused by adriamycin, a DNA damaging drug (Figure 6b ). This indicates that cytotoxicity induced by DNA damaging drugs but not cytotoxicity induced by inhibitors of the proteasome may depend on wt p53.
To evaluate the role of p21, a p53-responsive and proteasome-degraded protein, we took advantage of cells in which alleles of p21 were selectively knocked-out. 37 We compared the sensitivity of HCT116 parental cells with HCT116 p21−/− cells, a clone of HCT116 cells lacking p21 (Figure 7) . Although HCT116 cells were slightly more sensitive to cytostatic (low) doses of proteasome inhibitor than p21−/− cells, p21 is dispensable for PS-341 cytotoxicity. HCT116 cells or HCT116 cells lacking p21 (p21−/−) were incubated with ALLN for 3 days, and then the MTT assay was performed as described in Methods.
both cell lines were equally sensitive to cytotoxic (higher) doses of proteasome inhibitor. A similar result has been recently reported by Wagenknecht et al. 24 Also, inhibition of p21 did not affect apoptosis by chemotherapy in HL60 cells. 57 This indicates that although p21 may be involved in growth arrest, it does not contribute to cell death caused by proteasome inhibitor.
Discussion
An increasing number of studies have shown that selective and nonselective inhibitors of proteolysis can induce cell death. [15] [16] [17] [18] [19] [20] [21] [22] [23] The data presented here demonstrate that in the cell lines studied proteasome inhibition is the anti-proteolytic component responsible for the cytostatic and the apoptotic activities of these inhibitors. Thus: (1) although ALLN and ALLM are equally potent inhibitors of calpain and cathepsins, 42 ALLN is 20 times more potent as an inhibitor of growth and survival than ALLM, which corresponds to their anti-proteasome activities; 17 (2) the highly selective inhibitor of the proteasome, PS-341, was much more cytotoxic than the less selective inhibitors ALLN and ALLM; and (3) selective inhibitors of calpain were not cytotoxic.
Proteasome inhibitors but not calpain inhibitors induced wt p53 in the tested cell lines. In agreement with a previous report, 34 we found that 20 times higher doses of ALLM than ALLN were required to induce wt p53. In accord with Lopes et al, 16 a highly selective calpain inhibitor did not significantly induce wt p53. 58 In contrast, selective proteasome inhibitors such as lactacystin 32, 44 and PS-341 30 induced wt p53 as potently as ALLN.
Importantly, our data suggest that wt p53 does not play a role in proteasome inhibitor-induced apoptosis, even though both wt p53 accumulation and apoptosis are caused by inhibition of the proteasome. Thus: (1) apoptosis occurred in cell lines lacking wt p53; (2) accumulation of wt p53 does not ensure apoptosis in MCF-7 cells; and (3) introduction of wt p53 in p53-null cells does not increase their sensitivity to proteasome inhibitors. Likewise, p21 is a marker of proteasome inhibition but is neither sufficient nor necessary for apoptosis.
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Induction of other tumor suppressors such as p27, which are degraded by the proteasome, 59 is associated with cytotoxicity caused by proteasomes inhibition 17 which might lead to the conclusion that p27 causes apoptosis. Our study suggests an explanation for this association: the accumulation of proteasome-degraded proteins such as p53, p21 and p27 is a marker of efficient inhibition of the proteasome, and therefore should be associated with apoptosis caused by proteasome inhibitors. However, p53, p21, p27 and p57 are likely to play a role in growth arrest induced by proteasome inhibitors; 60 this may be masked by apoptosis. Growth arrest was observed in MCF-7 cells lacking caspase-3.
Cell lines are varied in their general ability to undergo apoptosis, and it is possible to distinguish apoptosis-prone and -resistant cell lines. Apoptosis-resistant phenotype can be illustrated by inhibition of caspases by CrmA which causes resistance of leukemic cells to multiple chemotherapeutic agents, 61 and common crossresistance in induction of apoptosis by different cytotoxic regimens. 62 In comparison with Jurkat and HL-60 cells, K562 cells are relatively resistant to apoptosis induced by a variety of stimuli, potentially because caspase-3 activation is delayed in K562 cells. [49] [50] [51] [52] Here, we found that proteasome inhibitor-induced apoptosis is delayed in K562 cells compared to other leukemia cells studied.
The selective proteasome inhibitor, PS-341, is effective in nanomolar concentrations. Importantly, proteasome inhibitors do not induce bone marrow toxicity in animal studies. 21 Thus, the selective proteasome inhibitor with its ability to induce apoptosis represents a novel class of experimental therapeutics which are highly active against leukemia cells with mutant p53.
